BeOne Medication presents a clear strategic vision: the development of innovative, high-quality, and accessible oncology medications for patients around the world.
The company operates with a convention-breaking approach that combines scientific excellence, clinical efficiency, and a broad social perspective—recognizing that true innovation is also measured by its ability to reach those who need it most.
BeOne is committed to developing therapies that are not only advanced in research and technology, but also attainable for patients and communities beyond the major markets. This approach is reflected in a robust development pipeline, investment in global clinical trials, and a focus on unmet medical needs.
This vision aligns naturally with the work of Haverim L’Refuah, which is dedicated to strengthening pharmaceutical security and improving access to essential medication for patients in Israel. The partnership reflects a shared commitment to reducing gaps and transforming medical innovation into meaningful value for patients.
Sincerely,
Itzik Mizrahi
CEO, BeOne Medication Israel
